# Kyverna Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Kyverna Therapeutics, Inc.). ## Overview Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead program, KYV-101, is being advanced in late-stage trials for conditions such as myasthenia gravis, stiff person syndrome, and lupus nephritis, with additional exploration in multiple sclerosis. ## Products & services • KYV-101 autologous cell therapy for autoimmune disease • KYSA-6 clinical program in myasthenia gravis and stiff person syndrome • KYSA-1 and KYSA-3 clinical programs in lupus nephritis • KYV-102 preclinical/IND-stage autoimmune program • Cell manufacturing, vector development, and clinical trial execution - **Lead cell therapy programs** (0%) — Clinical-stage autologous cell therapy candidates designed to reset autoimmune disease activity. - **Pipeline expansion programs** (0%) — Earlier-stage and additional indications built around the same autoimmune cell therapy platform. - **Manufacturing and process development** (0%) — Third-party cell manufacturing, release testing, and vector process development supporting trials. - **Collaboration and licensing activities** (0%) — Strategic alliances and licensing arrangements used to fund and extend the pipeline. - KYV-101 autologous cell therapy for autoimmune diseases - KYSA-6 program for myasthenia gravis and stiff person syndrome - KYSA-1 and KYSA-3 programs for lupus nephritis - KYV-102 next-generation autoimmune product candidate - Clinical development, regulatory, and manufacturing activities - Lentiviral vector process development and cell therapy supply chain ## Customers Kyverna does not yet sell approved products; its direct 'customers' are primarily clinical trial patients and the physicians, hospitals, and research centers running its studies. In a commercial setting, the company would ultimately serve specialty neurologists, rheumatologists, and transplant-style treatment centers that manage severe autoimmune disease. It also depends on contract manufacturers, research collaborators, and licensing partners to advance its programs. - **Clinical trial patients** (primary) — Patients with autoimmune diseases enrolled in KYV-101 and related studies to evaluate safety and efficacy. - **Investigators and trial sites** (primary) — Hospitals, academic centers, and clinicians that recruit patients, administer protocols, and generate data. - **Specialist prescribers** (secondary) — Neurology and nephrology specialists who would drive adoption if the therapies are approved. - **Manufacturing and development partners** (primary) — CMOs and vector suppliers that provide cell manufacturing, release testing, and process development. - **Strategic collaborators** (secondary) — Potential licensing or alliance partners that can provide capital, expertise, or commercialization support. - Clinical trial patients with severe autoimmune diseases - Investigators and academic medical centers running studies - Specialist physicians treating myasthenia gravis and lupus nephritis - Future treatment centers that would administer approved cell therapies - Strategic partners and licensors that fund or enable development ## Geography Kyverna is headquartered in the United States and its operating footprint is centered on U.S. clinical development and manufacturing support. The company uses third-party facilities in Pennsylvania for cell manufacturing and maintains office and laboratory space in Emeryville, California. It also has a supply relationship with Oxford Biomedica in the UK, which adds cross-border manufacturing and sourcing exposure. - United States is the core market for trials, operations, and future commercialization - Emeryville, California houses office and laboratory operations - Philadelphia, Pennsylvania supports customized cell manufacturing and testing - United Kingdom supply chain exposure through Oxford Biomedica - Future international expansion is mentioned but not yet a major revenue driver ## Strategy Kyverna is focused on advancing KYV-101 through late-stage clinical development and preparing for regulatory filings, including support for a BLA in stiff person syndrome and a registrational Phase 3 trial in myasthenia gravis. At the same time, it is broadening the pipeline with KYV-102 and additional autoimmune indications while building the manufacturing, regulatory, and commercial infrastructure needed for a potential launch. Because the company remains pre-revenue, capital preservation and access to financing are central to execution. - **Complete late-stage development of KYV-101** (short-term) — Regulatory success depends on generating pivotal data in myasthenia gravis and stiff person syndrome. - **Broaden the pipeline beyond KYV-101** (medium-term) — A broader autoimmune portfolio reduces single-asset dependence and increases long-term value creation. - **Build commercial and manufacturing readiness** (medium-term) — Cell therapies require specialized supply, release testing, and launch infrastructure before approval. - Advance KYV-101 through late-stage autoimmune trials - Prepare BLA and registrational filings for lead indications - Expand into additional autoimmune and neuroimmunology indications - Build manufacturing and commercial readiness before approval - Use partnerships and financing to extend runway ## Risks Kyverna is a pre-revenue biotech with a limited operating history, substantial accumulated losses, and ongoing dependence on external capital. Its value creation depends on successful clinical outcomes, regulatory approvals, and reliable third-party manufacturing, all of which are uncertain and can be delayed by scientific, operational, or macroeconomic factors. - **Clinical development failure or delay** [critical] — The company’s value depends on positive data and timely enrollment in KYV-101 trials. - **Financing and liquidity risk** [high] — The company has recurring losses and may need equity, debt, or partnership funding to continue operations. - **Third-party manufacturing dependence** [high] — Cell therapy supply relies on CMOs and vector partners, reducing control over quality, timing, and cost. - **Regulatory and approval risk** [high] — Late-stage programs must satisfy FDA and other regulators before commercialization can begin. - **Competitive and IP risk** [medium] — Competing autoimmune therapies and patent challenges could reduce market opportunity and exclusivity. - No approved products and no product sales to date - Clinical trial failure or delay could impair the lead asset - Dependence on third-party CMOs and vector suppliers - Need for additional capital may dilute shareholders - Autoimmune cell therapy competition could limit adoption - IP disputes or patent gaps could weaken exclusivity ## Accounting Kyverna’s reporting is dominated by R&D expense, stock-based compensation, and estimates tied to clinical development and manufacturing commitments. As a pre-commercial biotech, it has no product revenue, so investors should focus on how trial spending, lease obligations, and any collaboration or financing arrangements flow through the income statement and balance sheet. - **R&D expense accruals** — Trial timing can shift reported losses materially - **Lease accounting** — Emeryville lab lease and equipment leases - **Stock-based compensation** — Impacts operating loss and comparability - **Going-concern and liquidity assumptions** — Important for assessing dilution and execution risk - No product revenue; results are driven by R&D and G&A spending - Stock-based compensation can materially affect operating loss - Clinical and manufacturing accruals depend on trial progress and vendor invoices - Operating and finance leases affect balance sheet and cash needs - Capital raises and collaboration accounting can change reported cash runway --- *Last updated: 2026-04-28T20:20:48.471795+00:00*